Viral Vector Purification Market Report 2026

The viral vector purification market size has grown rapidly in recent years. It will grow from $1.75 billion in 2025 to $2.07 billion in 2026 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to growth in viral vector manufacturing activities, rising adoption of gene therapy research, early use of ultrafiltration and chromatography methods, increasing focus on vector safety, availability of purification reagents and kits.

The viral vector purification market size is expected to see rapid growth in the next few years. It will grow to $3.98 billion in 2030 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to increasing demand for clinical-grade viral vectors, rising investments in downstream bioprocessing technologies, expansion of gene therapy pipelines, growing adoption of automated purification platforms, increasing regulatory scrutiny on product purity. Major trends in the forecast period include increasing adoption of high-resolution chromatography techniques, rising demand for scalable purification solutions, growing use of single-use purification systems, expansion of high-purity vector isolation processes, enhanced focus on process yield optimization.

The increasing demand for gene therapies is expected to drive the growth of the viral vector purification market in the coming years. Gene therapies are treatments that involve adding, removing, or modifying genetic material within a patient’s cells to prevent or treat diseases. This demand is rising due to advancements in delivery systems, which allow safe, efficient, and targeted transport of genetic material into cells. Viral vector purification supports gene therapies by ensuring that viral vectors are high-quality, safe, and biologically active. It enhances treatment effectiveness by removing impurities and optimizing vector performance, promoting reliable and efficient therapeutic outcomes. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the Food and Drug Administration (FDA) approved six gene therapy products in 2023, compared with five approvals in 2022. Consequently, the growing demand for gene therapies is boosting the viral vector purification market.

Key players in the viral vector purification market are concentrating on rapid, high-throughput analytical solutions, such as macro mass photometry platforms, to improve process efficiency, ensure vector purity, and shorten development timelines. Macro mass photometry platforms are instruments that use light scattering to measure both the size and mass of viral particles, enabling precise evaluation of empty versus full capsids and detection of degraded particles within minutes. For instance, in November 2023, Refeyn Ltd., a UK-based biotechnology company, introduced KaritroMP, a macro mass photometry platform capable of analyzing adenovirus and lentivirus vectors in six minutes. The platform provides semi-automated processing for up to 13 samples, ensures high reproducibility for quality control, and allows detection of subtle differences in particle mass to support purification optimization. This launch strengthens viral vector manufacturers’ capabilities by offering faster and more accurate assessment of vector quality, streamlining workflows, and reducing time and resources required for vector characterization and purification.

In September 2025, Thermo Fisher Scientific Inc., a US-based scientific instruments and life sciences company, acquired Solventum’s purification and filtration business for approximately $4 billion. Through this acquisition, Thermo Fisher expands its bioprocessing portfolio by integrating Solventum’s advanced purification and filtration technologies to improve quality, efficiency, and end-to-end capabilities across upstream and downstream viral vector manufacturing processes. Solventum Corporation is a US-based healthcare company providing bioprocessing filtration and purification solutions, including products used in viral vector purification.

Major companies operating in the viral vector purification market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, FUJIFILM Diosynth Biotechnologies, Danaher Corporation, Sartorius AG, Agilent Technologies Inc., Eurofins Scientific SE, Charles River Laboratories International Inc., Bio‑Rad Laboratories Inc., AGC Biologics A/S, Takara Bio Inc., Miltenyi Biotec B.V. & Co. KG, Oxford Biomedica PLC, Revvity Inc., Applied Biological Materials Inc. (ABM), Creative Biolabs Inc., Repligen Corporation, Asahi Kasei Corporation, Promega Corporation, 3M Company.

North America was the largest region in the viral vector purification market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector purification market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector purification market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the viral vector purification market by increasing costs of imported chromatography resins, filtration membranes, analytical instruments, and specialized reagents used in downstream processing. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported purification technologies, while Asia-Pacific faces cost pressures on manufacturing scale-up. These tariffs are increasing purification costs and extending development timelines for gene therapy programs. At the same time, they are encouraging domestic production of purification consumables, regional supplier development, and innovation in cost-efficient purification technologies.

The viral vector purification market research report is one of a series of new reports that provides viral vector purification market statistics, including viral vector purification industry global market size, regional shares, competitors with a viral vector purification market share, detailed viral vector purification market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector purification industry. This viral vector purification market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vector purification is the process of isolating viral vectors from production impurities, such as host cell proteins, DNA, and other contaminants, to produce a highly pure and safe product. Its primary goal is to ensure that viral vectors are suitable for therapeutic use, maintaining both efficacy and safety in gene therapy applications.

The main vector types in viral vector purification include adenoviral vectors, lentiviral vectors, adeno-associated viral (AAV) vectors, retroviral vectors, and others. Adenoviral vectors are engineered viruses designed to deliver genetic material into cells, commonly used in gene therapy and vaccine development. Product types include kits, reagents, instruments, and services, employing purification techniques such as chromatography, ultrafiltration, precipitation, and more. Applications span gene therapy, vaccine development, research, and other areas, serving end users including pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and others.

The viral vector purification market includes revenues earned by entities through process development, analytical testing, formulation development, chromatography, ultrafiltration, precipitation, quality control, viral clearance validation, scale-up optimization, and stability testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.